// STATE LEGISLATION TRACKER

Hawaii HB 1246: RELATING TO CANNABIS.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Hawaii
Bill: HB 1246
Session: 2026
Filed: 2025-01-22
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

HB1246 appears to be a cannabis and hemp bill, not a peptide, compounding, telehealth, or clinician-scope bill. Based on the title, subjects, and pending-introduction status, it has no direct impact on compounded peptides, off-label peptide prescribing, FDA 503A/503B compounding, or peptide-related patient access.

Key Points

No apparent change to compounded peptide access or prescribing
No apparent change to NP, naturopathic, or telehealth peptide care
No apparent FDA 503A/503B compounding language from available details
Cannabis and hemp regulation may matter only to users also using those products

What to Watch For

Note Watch for full bill text after introduction to confirm it stays limited to cannabis and hemp.

Note If hemp rules expand, they may affect adjacent wellness markets but not peptide prescribing directly.

Note No peptide-specific controlled-substance or prescription-monitoring impact is visible from the available details.

Where the Bill Stands

The latest provided action says the bill is pending introduction, so it does not appear to be formally moving through committees yet.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws